 GSK PLC LSE:GSK, NYSE:GSK said the second-line applications of its cancer drug will be limited in scope. The front-line use of Zejula, which has been developed to treat epithelial ovarian, fallopian tube, or primary peritoneal cancers, remains unchanged. 